Penumbra’s CAVT Technology Receives FDA Clearance for the Treatment of Deep Vein Thrombosis

 BOLT-DVT, a recent prospective, multicenter Investigational Device Exemption (IDE) trial, demonstrated first-line use of computer assisted vacuum thrombectomy (CAVT) for DVT is safe and effective

Penumbra, Inc. (NYSE: PEN), the world’s leading thrombectomy company, announced that the U.S. Food and Drug Administration (FDA) has granted clearance for the treatment of deep vein thrombosis (DVT) to the company’s Lightning™ computer assisted vacuum thrombectomy (CAVT™) technology. This indication is supported by positive results from the BOLT-DVT Investigational Device Exemption (IDE) trial, which demonstrated the safety and efficacy of CAVT in treating DVT.

https://www.penumbrainc.com/press-releases/penumbras-cavt-technology-receives-fda-clearance-for-the-treatment-of-deep-vein-thrombosis-dvt/